These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 36238196)
21. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1. Jiang F; Chen Q; Wang W; Ling Y; Yan Y; Xia P J Hepatol; 2020 Jan; 72(1):156-166. PubMed ID: 31568800 [TBL] [Abstract][Full Text] [Related]
22. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208 [TBL] [Abstract][Full Text] [Related]
23. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Triggiani D; Donghia R; Crudele L; Rinaldi R; Sabbà C; Triggiani V; De Pergola G; Piazzolla G Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364937 [TBL] [Abstract][Full Text] [Related]
24. MiR-149 Compromises the Reactions of Liver Cells to Fatty Acid via its Polymorphism and Increases Non-Alcoholic Fatty Liver Disease (NAFLD) Risk by Targeting Methylene Tetrahydrofolate Reductase (MTHFR). An X; Yang Z; An Z Med Sci Monit; 2017 May; 23():2299-2307. PubMed ID: 28507283 [TBL] [Abstract][Full Text] [Related]
25. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease. Fernández-Tussy P; Fernández-Ramos D; Lopitz-Otsoa F; Simón J; Barbier-Torres L; Gomez-Santos B; Nuñez-Garcia M; Azkargorta M; Gutiérrez-de Juan V; Serrano-Macia M; Rodríguez-Agudo R; Iruzubieta P; Anguita J; Castro RE; Champagne D; Rincón M; Elortza F; Arslanow A; Krawczyk M; Lammert F; Kirchmeyer M; Behrmann I; Crespo J; Lu SC; Mato JM; Varela-Rey M; Aspichueta P; Delgado TC; Martínez-Chantar ML Mol Metab; 2019 Nov; 29():40-54. PubMed ID: 31668391 [TBL] [Abstract][Full Text] [Related]
26. Suppression of miR-30a-3p Attenuates Hepatic Steatosis in Non-alcoholic Fatty Liver Disease. Wang DR; Wang B; Yang M; Liu ZL; Sun J; Wang Y; Sun H; Xie LJ Biochem Genet; 2020 Oct; 58(5):691-704. PubMed ID: 32419060 [TBL] [Abstract][Full Text] [Related]
27. Gan-Jiang-Ling-Zhu decoction alleviates hepatic steatosis in rats by the miR-138-5p/CPT1B axis. Dang Y; Xu J; Zhu M; Zhou W; Zhang L; Ji G Biomed Pharmacother; 2020 Jul; 127():110127. PubMed ID: 32325349 [TBL] [Abstract][Full Text] [Related]
29. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease. Xu M; Zheng XM; Jiang F; Qiu WQ J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055 [TBL] [Abstract][Full Text] [Related]
30. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21. Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452 [TBL] [Abstract][Full Text] [Related]
32. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Hur W; Lee JH; Kim SW; Kim JH; Bae SH; Kim M; Hwang D; Kim YS; Park T; Um SJ; Song BJ; Yoon SK Int J Biochem Cell Biol; 2015 Jul; 64():265-76. PubMed ID: 25957914 [TBL] [Abstract][Full Text] [Related]
34. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
35. Overexpression of circ PTK2 suppresses the progression of nonalcoholic fatty liver disease via the miR-200c/SIK2/PI3K/Akt axis. Li Y; Cen CQ; Liu B; Zhou L; Huang XM; Liu GY Kaohsiung J Med Sci; 2022 Sep; 38(9):869-878. PubMed ID: 35791807 [TBL] [Abstract][Full Text] [Related]
37. The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome. Thomas G; Betters JL; Lord CC; Brown AL; Marshall S; Ferguson D; Sawyer J; Davis MA; Melchior JT; Blume LC; Howlett AC; Ivanova PT; Milne SB; Myers DS; Mrak I; Leber V; Heier C; Taschler U; Blankman JL; Cravatt BF; Lee RG; Crooke RM; Graham MJ; Zimmermann R; Brown HA; Brown JM Cell Rep; 2013 Oct; 5(2):508-20. PubMed ID: 24095738 [TBL] [Abstract][Full Text] [Related]
38. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway. Jin SS; Lin CJ; Lin XF; Zheng JZ; Guan HQ Ann Hepatol; 2022; 27(2):100584. PubMed ID: 34808393 [TBL] [Abstract][Full Text] [Related]
39. Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway. Zhou R; Lin C; Cheng Y; Zhuo X; Li Q; Xu W; Zhao L; Yang L Front Pharmacol; 2020; 11():600175. PubMed ID: 33746742 [TBL] [Abstract][Full Text] [Related]
40. miR-125b promotes the NF-κB-mediated inflammatory response in NAFLD via directly targeting TNFAIP3. Zhang Q; Yu K; Cao Y; Luo Y; Liu Y; Zhao C Life Sci; 2021 Apr; 270():119071. PubMed ID: 33515562 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]